New Melissa, Keith Robert
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
VA Eastern Colorado Health Care System, Denver, Colorado, USA.
F1000Res. 2018 Jan 16;7:61. doi: 10.12688/f1000research.12433.1. eCollection 2018.
Despite advances in targeted treatments, lung cancer remains a common and deadly malignancy, in part owing to its typical late presentation. Recent developments in lung cancer screening and ongoing efforts aimed at early detection, treatment, and prevention are promising areas to impact the mortality from lung cancer. In the past several years, lung cancer screening with low-dose chest computed tomography (CT) was shown to have mortality benefit, and lung cancer screening programs have been implemented in some clinical settings. Biomarkers for screening, diagnosis, and monitoring of response to therapy are under development. Prevention efforts aimed at smoking cessation are as crucial as ever, and there have been encouraging findings in recent clinical trials of lung cancer chemoprevention. Here we review advancements in the field of lung cancer prevention and early malignancy and discuss future directions that we believe will result in a reduction in the mortality from lung cancer.
尽管靶向治疗取得了进展,但肺癌仍然是一种常见且致命的恶性肿瘤,部分原因在于其典型的晚期表现。肺癌筛查的最新进展以及旨在早期发现、治疗和预防的持续努力是有望降低肺癌死亡率的领域。在过去几年中,低剂量胸部计算机断层扫描(CT)肺癌筛查已显示出具有降低死亡率的益处,并且在一些临床环境中已经实施了肺癌筛查计划。用于筛查、诊断和监测治疗反应的生物标志物正在研发中。旨在戒烟的预防工作一如既往地至关重要,并且在最近的肺癌化学预防临床试验中已经有了令人鼓舞的发现。在此,我们综述肺癌预防和早期恶性肿瘤领域的进展,并讨论我们认为将导致肺癌死亡率降低的未来方向。